{"id":48418,"date":"2022-09-15T12:02:25","date_gmt":"2022-09-15T10:02:25","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/kurin-inc-provides-update-on-litigation-activity\/"},"modified":"2022-09-15T12:02:25","modified_gmt":"2022-09-15T10:02:25","slug":"kurin-inc-provides-update-on-litigation-activity","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/kurin-inc-provides-update-on-litigation-activity\/","title":{"rendered":"Kurin, Inc. Provides Update on Litigation Activity"},"content":{"rendered":"
\n

SAN DIEGO–(BUSINESS WIRE)–Kurin, Inc., the inventor and manufacturer of the Kurin\u00ae<\/sup> blood culture collection sets, provides an update to the most recent moves by Magnolia Medical Technologies. This week, Magnolia filed a motion in the US District Court of Delaware for a permanent injunction, hoping to take Kurin off the market.\n<\/p>\n

<\/a><\/p>\n

\n\u201cWe are disappointed, but not surprised by their attempt to create a monopoly and deprive customers of the ability to choose the most appropriate solution for them,\u201d said Bob Rogers, CEO and Inventor of Kurin. \u201cWe will vigorously defend access to the best solution to the contaminated blood culture problem. Our experience over the past few years shows that hospitals have rejected Magnolia\u2019s Steripath product because it is unnecessarily complex and difficult to use. Kurin\u2019s innovation in developing a smaller, simpler device is a demonstration of how the intellectual property system should work in America and explains why we are the market leader. We will not be bullied by a venture-backed company who continues to spend their millions on litigation in hopes of creating a monopoly. We are heartened by the support of Kurin customers, and have been told they too are upset at Magnolia\u2019s attempts to use the legal system to reduce choice and negatively impact clinical outcomes.\u201d\n<\/p>\n

\nKurin\u2019s revolutionary approach to the contaminated blood culture problem is an elegantly simple, intuitive design that requires no additional user steps. Kurin passively sidelines potential contaminants during blood culture collection. Kurin is a simply better and more sustainable approach over conventional mechanical diversion. Contaminated blood cultures are a significant problem, as roughly one-third of the positive results are wrong, exposing these patients to unnecessary antibiotics, extending hospital stays and impacting larger community health issues, such as antimicrobial resistance and the life-threatening infections caused by C. diff<\/i>.\n<\/p>\n

\nAbout Kurin, Inc.<\/strong>\n<\/p>\n

\nKurin, Inc., a certified Minority Business Enterprise (MBE), is focused on the design, development, manufacture, marketing, and sale of products that help healthcare providers reduce contaminated blood cultures. Kurin, manufactured in San Diego, CA, has received FDA 510(k) market clearance. For more information about Kurin, visit the website at www.kurin.com<\/a>.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nMatt Heindel
\n
Kurin, Inc.
\n
858-752-9514
\n
mattheindel@kurin.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

SAN DIEGO–(BUSINESS WIRE)–Kurin, Inc., the inventor and manufacturer of the Kurin\u00ae blood culture collection sets, provides an update to the most recent moves by Magnolia Medical Technologies. This week, Magnolia filed a motion in the US District Court of Delaware for a permanent injunction, hoping to take Kurin off the market. \u201cWe are disappointed, but … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-48418","6":"format-standard","7":"category-industry"},"yoast_head":"\nKurin, Inc. Provides Update on Litigation Activity - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/kurin-inc-provides-update-on-litigation-activity\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Kurin, Inc. Provides Update on Litigation Activity - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"SAN DIEGO–(BUSINESS WIRE)–Kurin, Inc., the inventor and manufacturer of the Kurin\u00ae blood culture collection sets, provides an update to the most recent moves by Magnolia Medical Technologies. This week, Magnolia filed a motion in the US District Court of Delaware for a permanent injunction, hoping to take Kurin off the market. \u201cWe are disappointed, but ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/kurin-inc-provides-update-on-litigation-activity\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-09-15T10:02:25+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20220915005053\/en\/1570734\/21\/KurinLOGO.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/kurin-inc-provides-update-on-litigation-activity\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/kurin-inc-provides-update-on-litigation-activity\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Kurin, Inc. Provides Update on Litigation Activity\",\"datePublished\":\"2022-09-15T10:02:25+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/kurin-inc-provides-update-on-litigation-activity\\\/\"},\"wordCount\":374,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/kurin-inc-provides-update-on-litigation-activity\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220915005053\\\/en\\\/1570734\\\/21\\\/KurinLOGO.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/kurin-inc-provides-update-on-litigation-activity\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/kurin-inc-provides-update-on-litigation-activity\\\/\",\"name\":\"Kurin, Inc. Provides Update on Litigation Activity - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/kurin-inc-provides-update-on-litigation-activity\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/kurin-inc-provides-update-on-litigation-activity\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220915005053\\\/en\\\/1570734\\\/21\\\/KurinLOGO.jpg\",\"datePublished\":\"2022-09-15T10:02:25+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/kurin-inc-provides-update-on-litigation-activity\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/kurin-inc-provides-update-on-litigation-activity\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/kurin-inc-provides-update-on-litigation-activity\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220915005053\\\/en\\\/1570734\\\/21\\\/KurinLOGO.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220915005053\\\/en\\\/1570734\\\/21\\\/KurinLOGO.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/kurin-inc-provides-update-on-litigation-activity\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Kurin, Inc. Provides Update on Litigation Activity\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Kurin, Inc. Provides Update on Litigation Activity - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/kurin-inc-provides-update-on-litigation-activity\/","og_locale":"en_US","og_type":"article","og_title":"Kurin, Inc. Provides Update on Litigation Activity - Pharma Trend","og_description":"SAN DIEGO–(BUSINESS WIRE)–Kurin, Inc., the inventor and manufacturer of the Kurin\u00ae blood culture collection sets, provides an update to the most recent moves by Magnolia Medical Technologies. This week, Magnolia filed a motion in the US District Court of Delaware for a permanent injunction, hoping to take Kurin off the market. \u201cWe are disappointed, but ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/kurin-inc-provides-update-on-litigation-activity\/","og_site_name":"Pharma Trend","article_published_time":"2022-09-15T10:02:25+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20220915005053\/en\/1570734\/21\/KurinLOGO.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/kurin-inc-provides-update-on-litigation-activity\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/kurin-inc-provides-update-on-litigation-activity\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Kurin, Inc. Provides Update on Litigation Activity","datePublished":"2022-09-15T10:02:25+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/kurin-inc-provides-update-on-litigation-activity\/"},"wordCount":374,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/kurin-inc-provides-update-on-litigation-activity\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220915005053\/en\/1570734\/21\/KurinLOGO.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/kurin-inc-provides-update-on-litigation-activity\/","url":"https:\/\/pharma-trend.com\/en\/kurin-inc-provides-update-on-litigation-activity\/","name":"Kurin, Inc. Provides Update on Litigation Activity - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/kurin-inc-provides-update-on-litigation-activity\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/kurin-inc-provides-update-on-litigation-activity\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220915005053\/en\/1570734\/21\/KurinLOGO.jpg","datePublished":"2022-09-15T10:02:25+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/kurin-inc-provides-update-on-litigation-activity\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/kurin-inc-provides-update-on-litigation-activity\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/kurin-inc-provides-update-on-litigation-activity\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20220915005053\/en\/1570734\/21\/KurinLOGO.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20220915005053\/en\/1570734\/21\/KurinLOGO.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/kurin-inc-provides-update-on-litigation-activity\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Kurin, Inc. Provides Update on Litigation Activity"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/48418","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=48418"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/48418\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=48418"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=48418"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=48418"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}